Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design

The peptide hormone relaxin (RLX), also available as clinical-grade recombinant protein (serelaxin), holds great promise as a cardiovascular and anti-fibrotic agent but is limited by the pharmacokinetic issues common to all peptide drugs. In this study, by a computational modelling chemistry approac...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Annunziata D'Ercole, Silvia Nistri, Lorenzo Pacini, Alfonso Carotenuto, Federica Santoro, Anna Maria Papini, Ross A. D. Bathgate, Daniele Bani, Paolo Rovero
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Frontiers Media S.A. 2022-08-01
Cyfres:	Frontiers in Pharmacology
Pynciau:	relaxin RXFP1 relaxin analogues cAMP ERK1/2 RXFP1 agonists
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fphar.2022.942178/full
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!